Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Regan Thomson
Northwestern University, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Microbial Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Thomson is a founder of and has equity interests in Microbial Pharmaceutical. Microbial Pharmaceutical aims to create a pipeline to feed compounds from the natural world into pharmaceutical research. Microbial Pharmaceuticals has developed a platform, metabologenomics, that allows the study of the compounds that a class of bacteria produces rather than focusing on a single compound at a time.
This NIH research involves a genome-enabled metabolomics approach (a.k.a., ~metabologenomics~) to correctly identify natural products and correlate them with their biosynthetic gene clusters.
Because Microbial Pharmaceutical’s commercial pursuits relate to metabologenomics, Professor Thomson relationship with the company and his involvement in this Northwestern research presents a potential conflict of interest that should be managed.
Targeted discovery of anti-proliferative natural products using genomics and metabolomics
Project Narrative The proposed research will lead to improvements in public health by providing an accelerated, targeted approach to the discovery and development of new natural product drug leads from microbes for the treatment of cancer. This goal will be achieved using a correlative approach that combines modern genomics, metabolomics, bioinformatics, and natural products discovery techniques to isolate and characterize novel secondary metabolite structures containing reductase-enabled moieties, which have been proven to be privileged for anti-proliferative bioactivity.
Filed on July 05, 2017.
Tell us what you know about Regan Thomson's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Regan Thomson”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Regan Thomson | Northwestern University | Conflict of Interest | Microbial Pharmaceutical | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.